J. Charles Jennette | |
---|---|
Born | |
Occupations |
|
Awards |
|
Academic background | |
Education |
|
Alma mater | |
Academic work | |
Institutions |
|
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019.[1]
Jennette's research focuses on understanding the causes of kidney diseases, particularly those induced by inflammatory and immunologic mechanisms, and improving the diagnosis and treatment of these diseases.[1] He has authored and edited books, book chapters and articles in medical journals, and is an editor of four editions of the nephropathology textbook titled Heptinstall's Pathology of the Kidney. He has more than 25 named lectureships including the UNC School of Medicine 2015 Norma Berryhill Distinguished Lecture.[2] He is the recipient of the Order of the Long Leaf Pine Award from the Governor of North Carolina for exemplary service to the State,[3] Distinguished Service Award of the Association of Pathology Chairs,[4] UNC Medical Alumni Distinguished Faculty Award, and Robert H. Heptinstall Lifetime Achievement Award from the Renal Pathology Society.[5]
Jennette served as the founding Secretary Treasurer of the Renal Pathology Society from 1993 until 1998, was elected vice president in 2003, and became president in 2004. He also served as President of the Association of Pathology Chairs from 2008 until 2010.[6]
Jennette received his Bachelor of Science in Zoology from the University of North Carolina at Chapel Hill in 1969 and received his M.D. from the UNC School of Medicine in 1973. From 1973 to 1977 he completed anatomic and clinical pathology residency training at UNC, as well as an immunopathology research fellowship at Scripps Clinic and Research Foundation in La Jolla, California.[1]
Jennette began his faculty career in 1978 as an instructor of pathology at the School of Medicine at the University of Carolina at Chapel Hill. He was appointed assistant professor of pathology in 1978, promoted to associate professor of pathology in 1985, and Professor of Pathology in 1991. From 1999 to 2019, he served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the UNC School of Medicine, and as Chief of Pathology and Laboratory Medicine Services at UNC Hospitals.[1]
From 1978 to 2019, Jennette was Director/Executive Director of the UNC Nephropathology Laboratory. He and his faculty associates established this regional nephropathology diagnostic service.[5]
In 2019, Jennette stepped down as Chair of Pathology and Laboratory Medicine. He continues to hold a faculty position as Professor of Pathology and Laboratory Medicine in the Division of Nephropathology, and Professor of Medicine in the Division of Nephrology and Hypertension at UNC Chapel Hill.[6]
Jennette's research encompasses clinical research based on evaluation of data obtained from patient medical records, clinical laboratory data, and pathologic evaluation of kidney biopsy specimens; basic research based on experimental investigations using specimens from patients or animal models of kidney disease; and translational research designed to apply (translate) basic research discoveries into improved diagnosis and treatment of disease in patients. Ronald J. Falk has been a colleague in many of his research works.[7]
Jennette and his associates have performed and published clinical and clinicopathologic studies, and recommendations for the management, diagnosis, and classification of kidney diseases. He was a member of consensus groups that published recommendations for pathologic diagnosis of kidney transplant rejection,[8] focal segmental glomerulosclerosis,[9] IgA nephropathy,[10] membranoproliferative glomerulonephritis,[11] C1q nephropathy,[12] membranous nephropathy,[13] lupus nephritis,[14] and ANCA glomerulonephritis.[15]
In 1994 and 2012, Jennette and his associate Falk led two international consensus conferences that standardized the names and pathologic features of different forms of vascular inflammation (vasculitis).[16][17][18]
Jennette and Falk established the Glomerular Disease Collaborative Network (GDCN) in 1985 to promote collaborative research on glomerular disease among UNC faculty in nephrology and nephropathology, along with community practice nephrologists who refer kidney biopsies to UNC for diagnosis.[7]
Clinical and clinicopathologic research projects have utilized GDCN resources, including the article published by Jennette and Falk in The New England Journal of Medicine in 1988, which reported the discovery that one major antigen target of ANCA is myeloperoxidase (MPO-ANCA) and clarified the diverse clinical and pathologic spectrum of ANCA disease, using data and samples obtained through the GDCN.[19] In 1990, they documented that the other major antigen specificity of ANCA is proteinase 3 (PR3-ANCA).[20]
One of Jennette's clinical research associates is his daughter, Caroline Poulton, who is the Director of Research Operations for the UNC Kidney Center.[21] They are co-authors on 20 journal articles that focus on various clinical aspects of kidney disease with the goal of improving patient outcomes, such as a study to optimize treatment outcomes for patients with ANCA vasculitis.[22]
Jennette, in collaboration with Falk, and UNC faculty associates Hong Xiao and Peiqi Hu, and other faculty and trainees, made multiple discoveries about the cellular and molecular mechanisms that cause ANCA disease. He, Falk, and their research associates published the first demonstration that ANCA can activate neutrophils in vitro,[23] and the first in vivo animal model confirming that ANCA antibodies cause glomerulonephritis by inducing glomerulonephritis and vasculitis in mice by intravenous injection of anti-MPO antibodies.[24] This model has been used to make discoveries about the pathogenesis of ANCA disease, including the discovery of a key role for alternative complement pathway activation[25] and C5a receptor engagement, which can be targeted by a novel small molecular inhibitor of C5a receptor (Avacopan).[26] This approach to therapy was FDA-approved for patient care in 2021.[27]
Jennette is married to Yvonne Jennette. They have two daughters, Jennifer Jennette, and Caroline Poulton; and three grandchildren.[28]